Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Macugen | Pegaptanib sodium | Macular degeneration, age-related | Do not list | Complete | ||
| Xolair | Omalizumab | Asthma, severe persistent | Do not list | Complete | ||
| Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
| Somavert | Pegvisomant | acromegaly | Do not list | Complete | ||
| Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
| Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
| Fosavance | Alendronate sodium/cholecalciferol | Osteoporosis | Do not list | Complete | ||
| Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | Do not list | Complete | ||
| Hepsera | Adefovir dipivoxil | Hepatitis B | Do not list | Complete | ||
| Enablex | Darifenacin hydrobromide | Bladder, overactive | Do not list | Complete |
Last Updated : April 29, 2024